Inositec secures $1.42m financing to advance new class of inositol hexaphosphate-based drug candidat
Inositec, which is engaged in the development of life-saving small molecule drugs based on inositol hexaphosphate (IP6), has closed a CHF1.4m ($1.42m) seed financing.
Investors participating in the round included VI Partners via the Venture Incubator fund and Zürcher Kantonalbank. The proceeds will be used to progress a drug candidate from Inositec’s proprietary Inositune platform through preclinical proof-of-concept.
